Clinical Trial Update: Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of the combination of inotuzumab ozogamicin and temsirolimus in relapsed or refractory CD22+ B-cell non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Cristiana Sessa | Conditions: B-cell Lymphoma Refractory | Phase 1 | Status: COMPLETED